<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01054144</url>
  </required_header>
  <id_info>
    <org_study_id>MCC-16018</org_study_id>
    <secondary_id>108562</secondary_id>
    <secondary_id>RV-MM-PI-0454</secondary_id>
    <nct_id>NCT01054144</nct_id>
  </id_info>
  <brief_title>Study of Single Agent Lenalidomide in Older Adults With Newly Diagnosed Multiple Myeloma</brief_title>
  <official_title>Phase II Study of Response Adapted Therapy Using Single Agent Lenalidomide in Older Adults With Newly Diagnosed, Standard Risk Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>H. Lee Moffitt Cancer Center and Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Celgene</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>H. Lee Moffitt Cancer Center and Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research is to estimate the effectiveness of a response adapted approach&#xD;
      with the use of the drug, lenalidomide in the treatment of older adults with newly diagnosed&#xD;
      standard risk multiple myeloma. This means that participants will be given the study drug,&#xD;
      lenalidomide but depending on how they respond to this drug they may also be given&#xD;
      dexamethasone and/or prednisone to help with their treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Summary: Patients will be started on the study drug, lenalidomide on Day 1, Cycle 1.&#xD;
      Lenalidomide is a capsule that is to be taken orally (by mouth). If the patient's disease&#xD;
      progresses after 2 cycles of therapy, a low dose of dexamethasone will be added. If the&#xD;
      patient's disease is stable after 2 cycles of therapy, the use of an alternate corticosteroid&#xD;
      (prednisone) will be added to the lenalidomide therapy they are receiving. Dexamethasone and&#xD;
      prednisone are in tablet form and will be taken orally (by mouth). However, if the patient&#xD;
      has a minimal response after an additional 2 cycles of lenalidomide therapy, the therapy will&#xD;
      be continued until their disease progresses. See the intervention descriptions for further&#xD;
      details.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 14, 2010</start_date>
  <completion_date type="Actual">November 24, 2020</completion_date>
  <primary_completion_date type="Actual">August 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Combined Therapy - Median Progression Free Survival</measure>
    <time_frame>up to 36 months</time_frame>
    <description>Progression free survival (PFS) of older adults with mildly symptomatic multiple myeloma treated on this response adapted approach (i.e. time from start of lenalidomide to failure of lenalidomide and low dose dexamethasone)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response Rate</measure>
    <time_frame>Every 8 weeks up to 12 months</time_frame>
    <description>Response rate in older adults with mildly symptomatic multiple myeloma to single agent lenalidomide, lenalidomide prednisone and lenalidomide low dose dexamethasone in patients with suboptimal responses to lenalidomide monotherapy. The study used the uniform response assessment of the International Myeloma Working Group with the addition of MR (minimal response) (Durie et al, 2006; Kumar et al, 2016). MR was defined as a 25-49% decrease in serum M spike, and a 50-89% improvement in urine M spike. For patients without a measurable serum or urine M spike, a 25-49% decrease in the difference between the involved and uninvolved free light chains was required. The response in this trial is defined as complete remission (CR), stringent complete remission (SRC), very good partial remission (VGPR) and partial remission (PR) and minimal response (MR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Serious Adverse Events</measure>
    <time_frame>Day 1 through Off Study Date, an average of 48 months</time_frame>
    <description>Number of participants with serious adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Single Agent - Median Progressive Free Survival (PFS)</measure>
    <time_frame>First measure at 8 weeks</time_frame>
    <description>The progression free survival of patients treated with single agent lenalidomide</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With 1 Year Overall Survival (OS)</measure>
    <time_frame>1 Year</time_frame>
    <description>The 1 year overall survival of older adults with mildly symptomatic multiple myeloma treated on this response adapted approach</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Response Adapted Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lenalidomide, prednisone and dexamethasone as outlined in Intervention Descriptions.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenalidomide</intervention_name>
    <description>Starting Dose: 25 mg by mouth (PO) days 1-21 of a 28 days cycle;&#xD;
Dose Level -1: 15 mg PO days 1-21 of a 28 days cycle;&#xD;
Dose Level -2: 10 mg PO days 1-21 of a 28 days cycle;&#xD;
Dose Level -3: 5 mg PO days 1-21 of a 28 days cycle;&#xD;
Dose Level -4: Discontinue</description>
    <arm_group_label>Response Adapted Therapy</arm_group_label>
    <other_name>Revlimid®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>Starting Dose: 100 mg PO days 1-5 every 28 days;&#xD;
Dose level -1: 50 mg PO days 1-5 of a 28 day cycle;&#xD;
Dose level -2: 25 mg PO days 1-5 of a 28 day cycle;&#xD;
Dose level -3: Discontinue</description>
    <arm_group_label>Response Adapted Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Starting Dose: 40 mg daily on days 1 - 4 every 28 days;&#xD;
Dose level -1: 20 mg daily on days 1 - 4 every 28 days;&#xD;
Dose level -1a: 40 mg daily on days 1, 2, and 3 followed by 20 mg on day 4 followed by 12 mg on day 5 followed by 8 mg on day 6;&#xD;
Dose level -2: 10 mg daily on days 1 - 4 every 28 days;&#xD;
Dose level -3: Discontinue</description>
    <arm_group_label>Response Adapted Therapy</arm_group_label>
    <other_name>Decadron</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Understand and voluntarily sign an informed consent form&#xD;
&#xD;
          -  Age ≥65 years or not eligible for high dose therapy and autologous stem cell&#xD;
             transplant&#xD;
&#xD;
          -  Able to adhere to study visit schedule and other protocol requirements&#xD;
&#xD;
          -  Diagnosed with multiple myeloma and considered to have active disease. Patients must&#xD;
             not have received an active chemotherapy regimen or Dexamethasone. Patients may have&#xD;
             received palliative radiotherapy at least 2 weeks prior to the study start.&#xD;
&#xD;
          -  Measurable myeloma paraprotein levels in serum (≥ 0.5 g/dL), urine (≥ 0.2 g excreted&#xD;
             in a 24-hour urine collection sample) or by serum free light chains (involved free&#xD;
             light chain greater than 100mg/L)&#xD;
&#xD;
          -  Eastern Cooperative Group (ECOG) Performance Status of 0 or 1&#xD;
&#xD;
          -  Serum bilirubin levels ≤1.5 times the upper limit of the normal (ULN) range for the&#xD;
             laboratory&#xD;
&#xD;
          -  Serum aspartate transaminase (AST) or serum alanine transaminase (ALT) levels ≤2 x ULN&#xD;
&#xD;
          -  Adequate bone marrow function: Absolute neutrophil count ≥ 1,000 cells/mm³ (1.0 x&#xD;
             10^9/L); Platelets ≥ 100,000 /mm³&#xD;
&#xD;
          -  Hemoglobin &gt; 8 g/dL&#xD;
&#xD;
          -  Adequate renal function: Calculated creatinine clearance ≥ 30ml/min by Cockcroft-Gault&#xD;
             formula&#xD;
&#xD;
          -  Low risk myeloma is defined as the absence of the following adverse features[21]:&#xD;
             t(4;14) by FISH or metaphase cytogenetics; t(14,16) or t(14;20) by FISH or metaphase&#xD;
             cytogenetics; Deletion 17q13 by FISH; Deletion 13 by metaphase analysis; Aneuploidy by&#xD;
             metaphase analysis; Β2 microglobulin &gt; 5.5.&#xD;
&#xD;
          -  Able to tolerate one of the following thromboprophylactic strategies: aspirin, low&#xD;
             molecular weight heparin or warfarin (coumadin)&#xD;
&#xD;
          -  Must be registered into the mandatory RevAssist® program, and be willing and able to&#xD;
             comply with the requirements of RevAssist®.&#xD;
&#xD;
          -  Females of childbearing potential (FCBP) must have a negative serum or urine pregnancy&#xD;
             test with a sensitivity of at least 50 milli-international units per milliliter&#xD;
             (mIU/mL) within 10 14 days prior to and again within 24 hours of prescribing&#xD;
             lenalidomide (prescriptions must be filled within 7 days) and must either commit to&#xD;
             continued abstinence from heterosexual intercourse or begin TWO acceptable methods of&#xD;
             birth control, one highly effective method and one additional effective method AT THE&#xD;
             SAME TIME, at least 4 weeks before taking lenalidomide. FCBP must also agree to&#xD;
             ongoing pregnancy testing. Men must agree to use a latex condom during sexual contact&#xD;
             with a female of child bearing potential even if they have had a successful vasectomy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Ongoing severe infection requiring intravenous antibiotic treatment&#xD;
&#xD;
          -  Life expectancy of less than 3 months&#xD;
&#xD;
          -  Performance status of 2, 3 or 4&#xD;
&#xD;
          -  Prior malignancy, except for adequately treated basal cell or squamous cell skin&#xD;
             cancer, in-situ cervical cancer, or other cancer from which the patient has been&#xD;
             disease-free for at least 2 years&#xD;
&#xD;
          -  Solitary bone or solitary extramedullary plasmacytoma as the only evidence of plasma&#xD;
             cell dyscrasia&#xD;
&#xD;
          -  Uncontrolled medical problems such as diabetes mellitus, congestive heart failure,&#xD;
             coronary artery disease, hypertension, unstable angina, arrhythmias), pulmonary,&#xD;
             hepatic and renal diseases unless renal insufficiency is felt to be secondary to&#xD;
             multiple myeloma.&#xD;
&#xD;
          -  Any serious medical condition, laboratory abnormality, or psychiatric illness that&#xD;
             would prevent the subject from signing the informed consent form&#xD;
&#xD;
          -  Pregnant or lactating&#xD;
&#xD;
          -  Any condition, including the presence of laboratory abnormalities, which places the&#xD;
             patient at unacceptable risk if he/she were to participate in the study or confounds&#xD;
             the ability to interpret data from the study&#xD;
&#xD;
          -  Known hypersensitivity to thalidomide&#xD;
&#xD;
          -  Use of any other experimental drug or therapy within 28 days of baseline.&#xD;
&#xD;
          -  The development of erythema nodosum if characterized by a desquamating rash while&#xD;
             taking thalidomide or similar drugs&#xD;
&#xD;
          -  Any prior use of lenalidomide&#xD;
&#xD;
          -  Concurrent use of other anti-cancer agents or treatments&#xD;
&#xD;
          -  Known seropositive for or active viral infection with human immunodeficiency virus&#xD;
             (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV). Patients who are&#xD;
             seropositive because of hepatitis B virus vaccine are eligible.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rachid Baz, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>H. Lee Moffitt Cancer Center and Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center and Research Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.moffitt.org/research--clinical-trials/clinical-trials</url>
    <description>Moffitt Cancer Center Clinical Trials website</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>January 21, 2010</study_first_submitted>
  <study_first_submitted_qc>January 21, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 22, 2010</study_first_posted>
  <results_first_submitted>December 8, 2020</results_first_submitted>
  <results_first_submitted_qc>February 19, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">February 23, 2021</results_first_posted>
  <last_update_submitted>October 8, 2021</last_update_submitted>
  <last_update_submitted_qc>October 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Newly Diagnosed Standard Risk Multiple Myeloma</keyword>
  <keyword>Senior Adults</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Lenalidomide</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 15, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/44/NCT01054144/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Response Adapted Therapy</title>
          <description>Lenalidomide, prednisone and dexamethasone as outlined in Intervention Descriptions.&#xD;
Lenalidomide: - Starting Dose: 25 mg by mouth (PO) days 1-21 of a 28 days cycle;&#xD;
Dose Level -1: 15 mg PO days 1-21 of a 28 days cycle;&#xD;
Dose Level -2: 10 mg PO days 1-21 of a 28 days cycle;&#xD;
Dose Level -3: 5 mg PO days 1-21 of a 28 days cycle;&#xD;
Dose Level -4: Discontinue&#xD;
Prednisone: - Starting Dose: 100 mg PO days 1-5 every 28 days;&#xD;
Dose level -1: 50 mg PO days 1-5 of a 28 day cycle;&#xD;
Dose level -2: 25 mg PO days 1-5 of a 28 day cycle;&#xD;
Dose level -3: Discontinue&#xD;
Dexamethasone: - Starting Dose: 40 mg daily on days 1 - 4 every 28 days;&#xD;
Dose level -1: 20 mg daily on days 1 - 4 every 28 days;&#xD;
Dose level -1a: 40 mg daily on days 1, 2, and 3 followed by 20 mg on day 4 followed by 12 mg on day 5 followed by 8 mg on day 6;&#xD;
Dose level -2: 10 mg daily on days 1 - 4 every 28 days;&#xD;
Dose level -3: Discontinue</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Response Adapted Therapy</title>
          <description>Lenalidomide, prednisone and dexamethasone as outlined in Intervention Descriptions.&#xD;
Lenalidomide: - Starting Dose: 25 mg by mouth (PO) days 1-21 of a 28 days cycle;&#xD;
Dose Level -1: 15 mg PO days 1-21 of a 28 days cycle;&#xD;
Dose Level -2: 10 mg PO days 1-21 of a 28 days cycle;&#xD;
Dose Level -3: 5 mg PO days 1-21 of a 28 days cycle;&#xD;
Dose Level -4: Discontinue&#xD;
Prednisone: - Starting Dose: 100 mg PO days 1-5 every 28 days;&#xD;
Dose level -1: 50 mg PO days 1-5 of a 28 day cycle;&#xD;
Dose level -2: 25 mg PO days 1-5 of a 28 day cycle;&#xD;
Dose level -3: Discontinue&#xD;
Dexamethasone: - Starting Dose: 40 mg daily on days 1 - 4 every 28 days;&#xD;
Dose level -1: 20 mg daily on days 1 - 4 every 28 days;&#xD;
Dose level -1a: 40 mg daily on days 1, 2, and 3 followed by 20 mg on day 4 followed by 12 mg on day 5 followed by 8 mg on day 6;&#xD;
Dose level -2: 10 mg daily on days 1 - 4 every 28 days;&#xD;
Dose level -3: Discontinue</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="27"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Combined Therapy - Median Progression Free Survival</title>
        <description>Progression free survival (PFS) of older adults with mildly symptomatic multiple myeloma treated on this response adapted approach (i.e. time from start of lenalidomide to failure of lenalidomide and low dose dexamethasone)</description>
        <time_frame>up to 36 months</time_frame>
        <population>Number of participants who received response adaptive therapy</population>
        <group_list>
          <group group_id="O1">
            <title>Response Adapted Therapy</title>
            <description>Lenalidomide, prednisone and dexamethasone as outlined in Intervention Descriptions.&#xD;
Lenalidomide: - Starting Dose: 25 mg by mouth (PO) days 1-21 of a 28 days cycle;&#xD;
Dose Level -1: 15 mg PO days 1-21 of a 28 days cycle;&#xD;
Dose Level -2: 10 mg PO days 1-21 of a 28 days cycle;&#xD;
Dose Level -3: 5 mg PO days 1-21 of a 28 days cycle;&#xD;
Dose Level -4: Discontinue&#xD;
Prednisone: - Starting Dose: 100 mg PO days 1-5 every 28 days;&#xD;
Dose level -1: 50 mg PO days 1-5 of a 28 day cycle;&#xD;
Dose level -2: 25 mg PO days 1-5 of a 28 day cycle;&#xD;
Dose level -3: Discontinue&#xD;
Dexamethasone: - Starting Dose: 40 mg daily on days 1 - 4 every 28 days;&#xD;
Dose level -1: 20 mg daily on days 1 - 4 every 28 days;&#xD;
Dose level -1a: 40 mg daily on days 1, 2, and 3 followed by 20 mg on day 4 followed by 12 mg on day 5 followed by 8 mg on day 6;&#xD;
Dose level -2: 10 mg daily on days 1 - 4 every 28 days;&#xD;
Dose level -3: Discontinue</description>
          </group>
        </group_list>
        <measure>
          <title>Combined Therapy - Median Progression Free Survival</title>
          <description>Progression free survival (PFS) of older adults with mildly symptomatic multiple myeloma treated on this response adapted approach (i.e. time from start of lenalidomide to failure of lenalidomide and low dose dexamethasone)</description>
          <population>Number of participants who received response adaptive therapy</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36" lower_limit="29.7" upper_limit="NA">Not reached</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Response Rate</title>
        <description>Response rate in older adults with mildly symptomatic multiple myeloma to single agent lenalidomide, lenalidomide prednisone and lenalidomide low dose dexamethasone in patients with suboptimal responses to lenalidomide monotherapy. The study used the uniform response assessment of the International Myeloma Working Group with the addition of MR (minimal response) (Durie et al, 2006; Kumar et al, 2016). MR was defined as a 25-49% decrease in serum M spike, and a 50-89% improvement in urine M spike. For patients without a measurable serum or urine M spike, a 25-49% decrease in the difference between the involved and uninvolved free light chains was required. The response in this trial is defined as complete remission (CR), stringent complete remission (SRC), very good partial remission (VGPR) and partial remission (PR) and minimal response (MR).</description>
        <time_frame>Every 8 weeks up to 12 months</time_frame>
        <population>1 participant could not be evaluated for response.</population>
        <group_list>
          <group group_id="O1">
            <title>Response Adapted Therapy</title>
            <description>Lenalidomide, prednisone and dexamethasone as outlined in Intervention Descriptions.</description>
          </group>
          <group group_id="O2">
            <title>Single Agent Lenalidomide</title>
            <description>Participants treated with single agent lenalidomide</description>
          </group>
        </group_list>
        <measure>
          <title>Response Rate</title>
          <description>Response rate in older adults with mildly symptomatic multiple myeloma to single agent lenalidomide, lenalidomide prednisone and lenalidomide low dose dexamethasone in patients with suboptimal responses to lenalidomide monotherapy. The study used the uniform response assessment of the International Myeloma Working Group with the addition of MR (minimal response) (Durie et al, 2006; Kumar et al, 2016). MR was defined as a 25-49% decrease in serum M spike, and a 50-89% improvement in urine M spike. For patients without a measurable serum or urine M spike, a 25-49% decrease in the difference between the involved and uninvolved free light chains was required. The response in this trial is defined as complete remission (CR), stringent complete remission (SRC), very good partial remission (VGPR) and partial remission (PR) and minimal response (MR).</description>
          <population>1 participant could not be evaluated for response.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Complete Response &amp; Stringent Complete Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very Good Partial Response (VGPR)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Partial Response (PR)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Minimal Response (MR)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stable Disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overall Response &gt;/= PR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Serious Adverse Events</title>
        <description>Number of participants with serious adverse events</description>
        <time_frame>Day 1 through Off Study Date, an average of 48 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Response Adapted Therapy</title>
            <description>Lenalidomide, prednisone and dexamethasone as outlined in Intervention Descriptions.&#xD;
Lenalidomide: - Starting Dose: 25 mg by mouth (PO) days 1-21 of a 28 days cycle;&#xD;
Dose Level -1: 15 mg PO days 1-21 of a 28 days cycle;&#xD;
Dose Level -2: 10 mg PO days 1-21 of a 28 days cycle;&#xD;
Dose Level -3: 5 mg PO days 1-21 of a 28 days cycle;&#xD;
Dose Level -4: Discontinue&#xD;
Prednisone: - Starting Dose: 100 mg PO days 1-5 every 28 days;&#xD;
Dose level -1: 50 mg PO days 1-5 of a 28 day cycle;&#xD;
Dose level -2: 25 mg PO days 1-5 of a 28 day cycle;&#xD;
Dose level -3: Discontinue&#xD;
Dexamethasone: - Starting Dose: 40 mg daily on days 1 - 4 every 28 days;&#xD;
Dose level -1: 20 mg daily on days 1 - 4 every 28 days;&#xD;
Dose level -1a: 40 mg daily on days 1, 2, and 3 followed by 20 mg on day 4 followed by 12 mg on day 5 followed by 8 mg on day 6;&#xD;
Dose level -2: 10 mg daily on days 1 - 4 every 28 days;&#xD;
Dose level -3: Discontinue</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Serious Adverse Events</title>
          <description>Number of participants with serious adverse events</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Single Agent - Median Progressive Free Survival (PFS)</title>
        <description>The progression free survival of patients treated with single agent lenalidomide</description>
        <time_frame>First measure at 8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Single Agent</title>
            <description>Participants who were treated with single agent lenalidomide only</description>
          </group>
        </group_list>
        <measure>
          <title>Single Agent - Median Progressive Free Survival (PFS)</title>
          <description>The progression free survival of patients treated with single agent lenalidomide</description>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29" lower_limit="25.7" upper_limit="73.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With 1 Year Overall Survival (OS)</title>
        <description>The 1 year overall survival of older adults with mildly symptomatic multiple myeloma treated on this response adapted approach</description>
        <time_frame>1 Year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Response Adapted Therapy</title>
            <description>Lenalidomide, prednisone and dexamethasone as outlined in Intervention Descriptions.&#xD;
Lenalidomide: - Starting Dose: 25 mg by mouth (PO) days 1-21 of a 28 days cycle;&#xD;
Dose Level -1: 15 mg PO days 1-21 of a 28 days cycle;&#xD;
Dose Level -2: 10 mg PO days 1-21 of a 28 days cycle;&#xD;
Dose Level -3: 5 mg PO days 1-21 of a 28 days cycle;&#xD;
Dose Level -4: Discontinue&#xD;
Prednisone: - Starting Dose: 100 mg PO days 1-5 every 28 days;&#xD;
Dose level -1: 50 mg PO days 1-5 of a 28 day cycle;&#xD;
Dose level -2: 25 mg PO days 1-5 of a 28 day cycle;&#xD;
Dose level -3: Discontinue&#xD;
Dexamethasone: - Starting Dose: 40 mg daily on days 1 - 4 every 28 days;&#xD;
Dose level -1: 20 mg daily on days 1 - 4 every 28 days;&#xD;
Dose level -1a: 40 mg daily on days 1, 2, and 3 followed by 20 mg on day 4 followed by 12 mg on day 5 followed by 8 mg on day 6;&#xD;
Dose level -2: 10 mg daily on days 1 - 4 every 28 days;&#xD;
Dose level -3: Discontinue</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With 1 Year Overall Survival (OS)</title>
          <description>The 1 year overall survival of older adults with mildly symptomatic multiple myeloma treated on this response adapted approach</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse Events collected from consent through off treatment date, an average of 24 months. Serious Adverse events collected from consent to off-study date, an average of 48 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>All Participants</title>
          <description>All participants treated with Lenalidomide, prednisone and lenalidomide, prednisone and dexamethasone as outlined in Intervention Descriptions.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>General Cardiac Disorders - Other</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorders, other</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Colon Obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Hemorrhage, Stomach</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Coagulation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>General disorders - Other</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <description>Fever in the absence of neutropenia where neutropenia is defined as ANC &lt;1.0 x 10e9/L</description>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <description>Death not associated with CTCAE term - Sudden death</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Chest wall pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Limb pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Pain -Other</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Colitis, Infectious (e.g. Clostridium difficile)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Infection -Blood</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Infection - Lung</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Infection - Other</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Infection - Bladder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Hypercalcemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Investigations -Other</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle weakness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Secondary malignancy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Mental status</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Wound complication</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hemorrhage, CNS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Cerebrovascular ischemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Vascular -Other</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Non-myocardial vascular arterial ischemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutrophils/granulocytes</sub_title>
                <counts group_id="E1" events="265" subjects_affected="25" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" events="264" subjects_affected="22" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Low platelet count</sub_title>
                <counts group_id="E1" events="78" subjects_affected="20" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Hemoglobin, low</sub_title>
                <counts group_id="E1" events="75" subjects_affected="16" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Hemolysis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Pain - external ear</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Pain - eye</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="46" subjects_affected="24" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="66" subjects_affected="23" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="37" subjects_affected="17" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorders - Other</sub_title>
                <counts group_id="E1" events="13" subjects_affected="12" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="14" subjects_affected="11" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="12" subjects_affected="9" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Heartburn/dyspepsia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Distension/bloating, Abdominal</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Mucositis/stomatitis - oral cavity</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Hemorrhoids</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Obstruction, GI - Colon</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Abdominal Pain NOS</sub_title>
                <counts group_id="E1" events="18" subjects_affected="12" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Gallbladder pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="63" subjects_affected="23" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="20" subjects_affected="13" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Fever (in absence of neutropenia)</sub_title>
                <counts group_id="E1" events="25" subjects_affected="10" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Rigors/chills</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Diaphoresis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Constitutional symptoms - Other</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="45" subjects_affected="21" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Pain - extremity/limb</sub_title>
                <counts group_id="E1" events="29" subjects_affected="16" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="26" subjects_affected="16" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Joint pain</sub_title>
                <counts group_id="E1" events="12" subjects_affected="10" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Chest wall pain</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Chest/thorax pain</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Pain-throat/pharynx/larynx</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Pain - stomach</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Pain - NOS</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Pain - lymph node</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Pain - oral, gum</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Breast pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Buttock pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Pain - dental</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Pain - face</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Oral cavity pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Pelvic pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Sinus pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Pain - testicle</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Edema - limb</sub_title>
                <counts group_id="E1" events="52" subjects_affected="21" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Edema -head and neck</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Edema - trunk</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Gait changes</sub_title>
                <counts group_id="E1" events="8" subjects_affected="5" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Gingivitus</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="11" subjects_affected="9" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Infection -Other</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Bronchus infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Eye infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Sinus infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Upper airway infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Conjunctiva infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Peripheral nerve infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Nail infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>wound infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Bladder infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Colon infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Tooth infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Mucosal infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="13" subjects_affected="9" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Creatinine</sub_title>
                <counts group_id="E1" events="14" subjects_affected="7" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>ALT, SGPT high</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Hyperbilirubinemia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="4" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Alkaline phosphatase</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Investigations - Other</sub_title>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Hypercalcemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="2" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>AST, SGOT</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Hypomagnesemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Hypernatremia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="27" subjects_affected="12" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" events="11" subjects_affected="8" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Weight gain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain - muscle</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Musculoskeletal and connective tissue disorders - Other</sub_title>
                <counts group_id="E1" events="19" subjects_affected="12" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Muscle weakess, generalized</sub_title>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Muscle weakness, extraocular</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Muscle weakness, lower extremities</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Fracture</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Muscle weakness, trunk</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Myositis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neuropathy, sensory</sub_title>
                <counts group_id="E1" events="38" subjects_affected="19" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="29" subjects_affected="15" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Nervous system disorders -Other</sub_title>
                <counts group_id="E1" events="15" subjects_affected="9" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" events="16" subjects_affected="8" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Neuropathy, motor</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>CNS cerebrovascular ischemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Memory impairment</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Neuropathy, cranial</sub_title>
                <description>CN VIII hearing and balance</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Speech impairment</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="9" subjects_affected="6" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Agitation/Iritability</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="6" subjects_affected="3" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Personality/Behavior changes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="28" subjects_affected="16" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="25" subjects_affected="14" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Respirator, thoracic and mediastrinal disorders -Other</sub_title>
                <counts group_id="E1" events="14" subjects_affected="9" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Loss or alteration of voice</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Bronchospasm, wheezing</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Paranasal/sinus reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Obstruction of airway</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin and subcutaneous tissue disorders -Other</sub_title>
                <counts group_id="E1" events="27" subjects_affected="14" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Rash/desquamation</sub_title>
                <counts group_id="E1" events="15" subjects_affected="14" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" events="18" subjects_affected="11" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Pruritus/itching</sub_title>
                <counts group_id="E1" events="18" subjects_affected="10" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Rash, erythema multiforme</sub_title>
                <counts group_id="E1" events="16" subjects_affected="10" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Brusing</sub_title>
                <counts group_id="E1" events="13" subjects_affected="9" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Hyperpigmentation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Nail changes</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Rash, acne/acneiform</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Wound complication, non-infectious</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <description>Dermatitis associated with chemoradiation</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Skin breakdown/decubitus ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" events="8" subjects_affected="5" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Rachid Baz, MD</name_or_title>
      <organization>Moffitt Cancer Center</organization>
      <phone>813-745-3163</phone>
      <email>Rachid.Baz@moffitt.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

